MDR-TB Close Contacts Tracing in China (TCCT Study)

Status Not yet recruiting

Clinical Trial Summary

To investigate the incidence of etiologically confirmed or clinically diagnosed active tuberculosis in close contacts of MDR-TB patients.

Clinical Trial Description

This study is a prospective observational cohort study. MDR-TB patients from multi-centers in China were continuously evaluated one by one, their close contacts were screened for elibgility. All subjects were followed for the same length of time: 80 weeks after enrollment. The symptoms and signs of tuberculosis were followed up to monitor the occurrence of tuberculosis.

The primary objective is to investigate the incidence of etiologically confirmed or clinically diagnosed active TUBERCULOSIS in close contacts of MDR-TB patients.

The secondary objective is to assess latent TB infection rates in close contacts of MDR-TB patients; evaluate the high risk factors of TUBERCULOSIS in close contact population; assess the loss rate of close contacts within 80 weeks; assess the 80-week mortality rate among close contacts; isolate the mycobacterium tuberculosis from all patients with active tuberculosis and analyze drug resistance to evaluate the homology and drug-resistant transmission pattern of Mycobacterium tuberculosis. ;

Study Design

Related Conditions & MeSH terms

Multidrug Resistant Tuberculosis
Tuberculosis
Tuberculosis, Multidrug-Resistant

Clinical Trial Details

NCT number	NCT04484129
Study type	Observational
Source	Huashan Hospital
Contact	Qiaoling Ruan, Dr.
Phone	(086)13661856002
Email	ruan_qiao_ling@163.com
Status	Not yet recruiting
Phase
Start date	July 21, 2020
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05017324` - Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial	N/A
Active, not recruiting	`NCT02496572` - Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan	Phase 3
Completed	`NCT03942354` - Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Completed	`NCT02454205` - An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis	Phase 2/Phase 3
Recruiting	`NCT05081401` - Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
Completed	`NCT01856634` - Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis	Phase 1
Active, not recruiting	`NCT03867136` - Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)	Phase 4
Completed	`NCT00727844` - Linezolid to Treat Extensively-Drug Resistant Tuberculosis	Phase 2
Completed	`NCT01859923` - A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)	Phase 2
Active, not recruiting	`NCT04421495` - Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China	Phase 4
Active, not recruiting	`NCT04717908` - Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS	N/A
Not yet recruiting	`NCT03604848` - NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB	N/A
Recruiting	`NCT02120638` - Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide	Phase 3
Recruiting	`NCT05534750` - Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)	Phase 2